Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.
Revenues increased to $811.085 million, beating the consensus of $774.34 million.
Sales jumped 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 million.
Also Read: Could Personalized Medicine Be Your Portfolio’s Next Big Winner? Find Out
Gross margin was 69%, and adjusted gross margin was 72%.
In addition, Exact Sciences shared initial results from an internal version of its colorectal cancer (CRC) blood test, showing sensitivities of 73% for CRC and 14% for APL at 90% specificity.
Internal testing and evaluation of the assay are ongoing.
Outlook
Exact Sciences raised its fiscal 2025 sales guidance from $3.07 billion-3.12 billion to $3.13 billion-$3.17 billion versus the consensus of $3.099 billion.
The guidance includes a Screening segment sales forecast of $2.44 billion-$2.47 billion, compared to previous guidance of $2.39 …